A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine

Int J Antimicrob Agents. 2023 Aug;62(2):106839. doi: 10.1016/j.ijantimicag.2023.106839. Epub 2023 May 7.
No abstract available

Publication types

  • Observational Study
  • Letter
  • Comment

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Canada
  • HIV Infections* / drug therapy
  • Humans
  • Lamivudine / therapeutic use
  • Nevirapine / therapeutic use
  • Oxazines / therapeutic use
  • Patient Acceptance of Health Care
  • Pyridones / therapeutic use
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Viral Load

Substances

  • Anti-HIV Agents
  • dolutegravir
  • Lamivudine
  • Nevirapine
  • Oxazines
  • Pyridones
  • Reverse Transcriptase Inhibitors

Supplementary concepts

  • Canadian people